A Phase 2, Open-Label, 2-C Cohort Study of INCB050465, A P13K@ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)

Administered By

Awarded By

Contributors

Start/End

  • June 6, 2017 - June 9, 2020